Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

TNFRSF8 (TNF Receptor Superfamily Member 8)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

›

TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 positive	Diffuse Large B Cell Lymphoma	TNFRSF8 positive	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
TNFRSF8 positive	Peripheral T-cell Lymphoma	TNFRSF8 positive	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	T Cell Non-Hodgkin Lymphoma	TNFRSF8 expression	T Cell Non-Hodgkin Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	Acute Myelogenous Leukemia	TNFRSF8 expression	Acute Myelogenous Leukemia	brentuximab vedotin Sensitive: C1 - Off-label brentuximab vedotin Sensitive : C1	brentuximab vedotin Sensitive: C1 - Off-label brentuximab vedotin Sensitive : C1
TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TT11 Sensitive: C2 – Inclusion Criteria TT11 Sensitive : C2	TT11 Sensitive: C2 – Inclusion Criteria TT11 Sensitive : C2
TNFRSF8 positive	Lymphoma	TNFRSF8 positive	Lymphoma	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	TT11 Sensitive: C3 – Early Trials TT11 Sensitive : C3	TT11 Sensitive: C3 – Early Trials TT11 Sensitive : C3